- Home
- INTS vs MDCX Comparison
INTS vs MDCX Comparison
Compare INTS & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTS
- MDCX
- Stock Information
- Founded
- INTS 2012
- MDCX 2008
- Country
- INTS United States
- MDCX Canada
- Employees
- INTS N/A
- MDCX N/A
- Industry
- INTS Biotechnology: Pharmaceutical Preparations
- MDCX
- Sector
- INTS Health Care
- MDCX
- Exchange
- INTS Nasdaq
- MDCX Nasdaq
- Market Cap
- INTS 35.3M
- MDCX 33.8M
- IPO Year
- INTS 2023
- MDCX N/A
- Fundamental
- Price
- INTS $2.36
- MDCX $3.16
- Analyst Decision
- INTS Strong Buy
- MDCX Strong Buy
- Analyst Count
- INTS 3
- MDCX 1
- Target Price
- INTS $8.50
- MDCX $10.00
- AVG Volume (30 Days)
- INTS 21.2K
- MDCX 106.5K
- Earning Date
- INTS 03-21-2025
- MDCX 01-01-0001
- Dividend Yield
- INTS N/A
- MDCX N/A
- EPS Growth
- INTS N/A
- MDCX N/A
- EPS
- INTS N/A
- MDCX N/A
- Revenue
- INTS N/A
- MDCX N/A
- Revenue This Year
- INTS N/A
- MDCX N/A
- Revenue Next Year
- INTS N/A
- MDCX N/A
- P/E Ratio
- INTS N/A
- MDCX N/A
- Revenue Growth
- INTS N/A
- MDCX N/A
- 52 Week Low
- INTS $1.50
- MDCX $1.80
- 52 Week High
- INTS $5.78
- MDCX $4.99
- Technical
- Relative Strength Index (RSI)
- INTS 54.23
- MDCX N/A
- Support Level
- INTS $2.17
- MDCX N/A
- Resistance Level
- INTS $2.43
- MDCX N/A
- Average True Range (ATR)
- INTS 0.20
- MDCX 0.00
- MACD
- INTS 0.02
- MDCX 0.00
- Stochastic Oscillator
- INTS 76.90
- MDCX 0.00
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.
About MDCX Medicus Pharma Ltd. Common Stock
Medicus Pharma Ltd is a clinical-stage, multi-strategy holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA approved clinical trials.